The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is in focus today after the company revealed that the US FDA has granted Fast Track designation for its NNZ-2591 treatment in Phelan-McDermid syndrome (PMS). This marks a significant milestone as there are currently no FDA-approved therapies for PMS.
Image source: Getty Images
What did Neuren Pharmaceuticals report?
- US FDA Fast Track designation granted to NNZ-2591 for PMS.
- NNZ-2591 is also Fast Tracked for Angelman and Pitt Hopkins syndromes.
- Koala Phase 3 trial for NNZ-2591 in PMS is underway in children aged 3–12.
- Positive Phase 2 clinical results in PMS, Pitt Hopkins, and Angelman syndromes.
- All NNZ-2591 indications have received "orphan drug" status in the US and EU.
- No FDA-approved treatments exist for PMS at present.
What else do investors need to know?
The Fast Track designation is designed to speed up both the development and review process of drugs targeting serious conditions with unmet needs. For Neuren, this means potentially quicker feedback and more communication from the FDA, and eligibility for accelerated or priority review pathways if trial results are strong.
Neuren's Koala trial is the first ever Phase 3 clinical trial in PMS, a rare condition impacting 1 in 8,000 to 15,000 people. NNZ-2591 is a key part of its strategy to develop therapies for critical childhood neurological disorders with limited or no available treatments.
What did Neuren Pharmaceuticals management say?
Commenting on the news, CEO Jon Pilcher said:
As we approach Phelan-McDermid Syndrome Awareness Day on 22 October, we are very pleased to announce Fast Track designation for our NNZ-2591 program. Neuren's Koala trial is the first ever Phase 3 clinical trial for PMS, which we hope may lead to a much-needed treatment for this community. We encourage all initiatives to increase awareness and diagnosis of PMS and applaud the leadership of both the Phelan-McDermid Syndrome Foundation and CureSHANK.
What's next for Neuren Pharmaceuticals?
Investors can watch for updates as Neuren progresses through its Koala Phase 3 trial for NNZ-2591 in children with PMS, plus ongoing development work in Angelman and Pitt Hopkins syndromes. With Fast Track and orphan drug designations in hand, Neuren has a clearer path to bring these potential treatments to communities in need, pending successful trial outcomes.
Neuren Pharmaceuticals share price snapshot
Neuren Pharmaceuticals shares have risen 74% over the past 12 months, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen around 8% over the same period.
